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http:WHAT THIS PAPER ADDS
This study shows that intra and post-operative results, achieved with this craniocaudal surgical technique,
compare favorably with those achieved with the conventional technique, as reported in the literature. As carotid
body tumors are rare and the surgical treatment has not been standardized, results can be disappointing. This
study, along with previous studies on the craniocaudal technique, offers the best available evidence that the
craniocaudal approach should be the surgical technique of choice.Objectives: To evaluate results after carotid body tumor (CBT) surgery using a novel dissection technique.
Methods: A retrospective analysis of all operated CBT in the last 6 years was carried out and results were
compared with the current literature and our previous series, which reported another 111 cases operated on
until 2005.
Results: Forty-ﬁve CBTs were removed in 41 (56% hereditary cases) patients (seven Shamblin I, 22 II, and 16 III).
There were no cases of permanent cranial nerve injury or stroke.
These pre- and postoperative results compare favorably with our previous series and are superior to, generally
smaller, studies reported in the contemporary literature.
Conclusions: This large series of surgically-treated CBTs supports craniocaudal dissection as the surgical technique
of choice as it limits blood loss and facilitates safe CBT resection.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Carotid body tumors (CBT), also known as carotid para-
gangliomas, are neoplasms localized in the bifurcation of
the common carotid artery. Like other paragangliomas,
these tumors are highly vascularized. Although considered
benign and slow-growing, growth of CBT is related to
neuropraxia of cranial nerves.1 Surgery is widely accepted
as the preferred treatment for CBT, with the goal of treating
or preventing local advancement of the tumor. In the early
stages of the CBT the aim of the surgical management is the
complete removal of CBT to prevent further growth and
incorporation of neurovascular structures, the latter leading
to increased intra-operative blood loss and postoperative
morbidity. In the more advanced stages surgery may be
indicated to relieve patient’s discomfort. Owing to these authors contributed equally.
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//dx.doi.org/10.1016/j.ejvs.2013.08.010properties of this tumor and its localization adjacent to
multiple neurovascular structures, the resection may be
extremely challenging.
Historically, the surgical procedure started by devascu-
larization of the CBT with ligation of the caudal feeding
branches from the external carotid artery. Subsequently,
resection of the CBT was started at the carotid bifurcation,
dissecting towards the cranial side.1 With this technique
there was still considerable intra-operative blood loss and
a signiﬁcant percentage of postoperative cranial nerve
damage (15e20%).2 In 2008, a modiﬁed operative tech-
nique was described whereby the dissection is performed
in a craniocaudal fashion.2 This technique is based upon
the course of the ascending pharyngeal artery, which is
suggested to be the tumor’s main proximal blood supply
and usually enters the CBT from its cranial side.3 The
craniocaudal approach carries the advantage of identifying
the adjacent nerves on the tumor’s cranial side at an early
stage to prevent accidental damage in case of hemorrhage
later during the operation. Compared with other studies
on conventional surgical techniques, this novel cranio-
caudal approach resulted in more favorable outcomes
considering blood loss and postoperative cranial nerve
damage.2
Table 1. Pre-operative characteristics of patients, tumors, and
diagnostics.
n % Mean
Total patients 41
Men 18 44
Women 23 56
Age (y) 38
Existence of complaints (mo) 31
Body mass index 24
Right-sided CBT 9 22
Left-sided CBT 8 20
Bilateral CBT 24 58
Family history of CBT 23 56
Computed tomography 1
Angiography 0
Magnetic resonance imaging 45
Pre-operative cranial nerve injury 13 29
Note. CBT ¼ carotid body tumor.
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operative practice at the Leiden University Medical Centre.
The aim of this study was to evaluate intra-operative blood
loss and postoperative outcomes of all surgically treated
CBT patients since 2005. In addition, the inﬂuence of tumor
and patient characteristics on postoperative outcome were
investigated and results were compared with the current
literature.
MATERIALS AND METHODS
A retrospective analysis was performed including all 45
consecutively operated CBTs in 41 patients at Leiden Uni-
versity Medical Center between 2006 and 2011. This
retrospective study did not require ethical review from our
institutional review board. All patients received low-
molecular heparin immediately pre-operatively and under-
went CBT surgery according to the craniocaudal method. In
short, the craniocaudal dissection technique is based upon
early identiﬁcation of the vagal, hypoglossal, and accessorial
nerves, control of the internal carotid artery, and ligation of
the ascending pharyngeal artery, all at the CBT’s cranial
side. Thereafter, dissection is carried out in a cranial-to-
caudal fashion.2 Data were studied and reported accord-
ing to pre, intra-, or postoperative periods.
All the tumors were classiﬁed by the Shamblin classiﬁ-
cation. Shamblin I tumors are small, localized tumors.
Shamblin II tumors approach surrounding vessels or partly
enclose them. Shamblin III tumors are large and fully
enclose adjacent vessels.4
The follow up consisted of a clinical check-up by both an
ear, nose, and throat specialist and a vascular surgeon. Fig. 1
shows how follow up is being performed at our institution.
Long-term follow up from our previous study2 was also done
to investigate what the recurrence rate of the CBT was in
craniocaudally approached CBTs. Data were reported as
mean  SD. To explore the correlation between two numeric
variables a scatterplot was used. To investigate whether
Shamblin classiﬁcation was of signiﬁcant inﬂuence on the
total intra-operative blood loss (as estimated by the amount
of used gauzes and suctioned blood in the container), a post
hoc one-way analysis of variance (ANOVA) was performed.
In order to explore the relationship between ShamblinFigure 1. Follow-up algorithm. Note. MRI ¼ magnetic resonance imag
result in a greater chance of developing chromafﬁne-positive pheochrclassiﬁcation and the occurrence of postoperative cranial
nerve damage, a linear-by-linear chi-square test for trends
was used. A ManneWhitney test was used to compare
numeric with categorical variables. p-values were considered
signiﬁcant if <.05.
Finally, the results of this study were compared with
other recent studies involving the surgical resection and
management of CBT, in which at least 10 patients were
included. A literature search was performed in PubMed. The
query consisted of the combination of two subjects: carotid
body tumor and surgery/resection. Results were limited to
articles published in English from 2005 onwards. The ﬁnal
search was performed on 14 June 2013. The search yielded
201 results (Supplementary Fig. S1).RESULTS
Between 2006 and 2011, 41 consecutive patients were
operated on. All patients were included in this study.
Table 1 shows the pre-operative characteristics of the
studied group. There were 18 men and 23 women, with a
mean age of 38 years (range, 16e61 years). Two patients
presented after testing positive for a SDHD mutation, and
proved to have CBT on imaging workup (n ¼ 2, 4.3%). Theing; CBT ¼ carotid body tumor. aSDHD and SDHB mutations both
omocytoma, but SDHB more often than SDHD.
Figure 2. Mean operative blood loss of 45 carotid body tumor
resections. Note. *p <.05 (post hoc one-way analysis of variance).
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leading to either mechanical or cosmetic complaints
(n ¼ 29, 61.7%). Another frequent complaint was problems
with swallowing (n ¼ 3, 6.4%), while tinnitus, dizziness, and
throat pain were less frequently, secondarily reported. In
total, 10 patients presented pre-operatively with neuro-
praxia, concerning the hypoglossal nerve (n ¼ 5) and the
marginal mandibular branch of the facial nerve (n ¼ 5).
In this study, 23 out of 41 (56%) patients suffered he-
reditary CBT. From these 23 patients 17 (74%) had bilateral
CBT. In total, 24 patients suffered bilateral CBT, with the
hereditary part being 17 (71%). Eight tumors were located
on the left (none of them were hereditary cases) and nine
tumors were located on the right, with six (66.7%) being of
hereditary origin.
Seven tumors were classiﬁed as Shamblin I, 22 as
Shamblin II, and 16 as Shamblin III. The mean gross size of
the tumors was 3 cm3 for the Shamblin I, 14 cm3 for the
Shamblin II, and 22 cm3 for the Shamblin III tumors.
All the patients underwent magnetic resonance imaging
(MRI) for preoperative diagnostics. One patient also un-
derwent computed tomography. None of the patients was
treated with pre-operative embolization.
The mean operation time was 210  99 minutes, and
overall mean blood loss was 129  120 mL. The blood loss
related to Shamblin classiﬁcation was 46  59 mL,
110  83 mL, and 189  150 mL for class I, II, and III,
respectively (Fig. 2). The peroperative blood loss during
Shamblin III CBT resection proved to be signiﬁcantly
increased compared with Shamblin I (p ¼ .008) and
Shamblin II (p ¼ .048, post hoc one-way ANOVA).
In four patients with generally larger tumors (Shamblin
III, n ¼ 3), extensive CBT incorporation of the arteries
necessitated total removal of the internal and external ca-
rotid artery followed by reconstruction of the ICA using
greater saphenous venous grafts. None of them suffered
from temporary postoperative cranial nerve damage. In four
patients, the external carotid artery had to be removed en
bloc with the CBT, of which one patient developed post-
operative transient neuropraxia.
In total, 12 patients (26.7%, of which one with preoper-
ative neuropraxia) suffered from temporary postoperativecranial nerve damage: ﬁve in the Shamblin II (29.4%) and
seven in the Shamblin III (77.8%) group. Temporary paresis
of the hypoglossal and facial (marginal mandibular branch)
nerves (both n ¼ 3) was most frequently reported, and all
resolved within 1 month. The linear-by-linear association
test showed that there was a signiﬁcant chance of devel-
oping postoperative temporary cranial nerve damage with
increasing Shamblin classiﬁcation (p ¼ .026).
In the present study no signiﬁcant correlation was found,
but there was a trend between peroperative blood loss and
development of postoperative neuropraxia (p ¼ .064). In
this series one patient (presenting with a Shamblin III CBT)
suffered from a minor non-disabling stroke concerning the
area of the right middle cerebral artery 7 days post-
operatively. The patient’s complaints resolved within a few
days and there was no persistent damage clinically and
diagnostically as computed tomography angiography and
MRI did not show ischemia. Including this case, there were
no reports of persistent cranial nerve damage amongst the
entire study group. Other postoperative complications were
bleeding (n ¼ 1) and superﬁcial wound infection (n ¼ 1),
which both needed re-operation.
The mean follow up was 2.5 years. During this period, no
deaths were reported and, to date, no recurrence or distant
metastasis of CBT have presented. One tumor proved to be
malignant as one regional metastatic lymph node was
found. Long-term follow up (mean of 11 years) from our
previous study shows a recurrence rate from 17% (7/42).
From those seven patients ﬁve were hereditary cases (71%).DISCUSSION
Considerable blood loss, persistent cranial nerve damage,
and stroke are complications encountered during and after
CBT surgery. While stroke has become a rare complication,
cranial nerve damage appears the most important adverse
outcome nowadays. The recent evaluation of surgically-
treated CBT cases after the introduction of a new cranio-
caudal approach2 suggested a considerable decrease of
these main complications. While in the previous series all
operations were performed or supervised by one surgeon,
the craniocaudal approach is now reproducible and per-
formed by all vascular surgeons at our institution.2
Todaydseveral years later with increased surgical experi-
ence on this subject and raised awareness of possible
complicationsdimproved results considering postoperative
morbidity can be expected. The present follow-up study is
one of the largest studies concerning the management of
CBT. The primary outcomes of the study were peroperative
blood loss and temporary or persistent cranial nerve
damage.
First, the mean estimated blood loss of 129 mL in the
present study compares favorably with other recently
published studies concerning the surgical management of
CBT (outlined in Table 2),2,5e16 as well as our previous se-
ries (mean estimated blood loss 281 mL).2 This difference
may be explained by the experience our institution has in
treating CBT as a result of the tertiary reference role. The
Table 2. Summary of larger (>10 carotid body tumors [CBT]) contemporary studies evaluating CBT management.
Study Years Patients
(n)
Men/
women
Mean
age (y)
CBT (n) Shamblin
(I,II,III)
PFH (%) PBL (mL) CND (%) Postoperative
stroke
Avgerinos et al.5 35 27 48/52 46 27 8,11,10 7 420/780/1366c e e
Desmond and
Christopher12
9 10 40/60 31 11 3,6,2 20 e 10 e
Ma et al.11 12 18 56/44 52 18 10,5,3 e e 0 e
Lim et al.6 ? 13 46/54 44b 15 1,4,8 0 280/700d 23 2
Kruger et al.10 25 39 44/56 49 49 ?,?,5 28 e 18.3 e
Ma et al.14 12 53 30/70 43b 57 16,30,11 6 e 6 2
Qin et al.7 25 33 47/53 36 33 3,2,9 0 860 e e
Makeieff et al.9 17 52 67/33 43 57 15,28,14 7 145/263d 14.03 1
Dalainas et al.13 20 17 12/88 48 18 3,6,8 0 e 5.8 0
Ozay et al.8 7 14 36/64 43 14 5,4,5 7 397 0 0
Fruhmann et al.16 25 50 17/33 55 63 13,28,22 2 e 0 1
Li-Shan et al.15,a 62 111 e e 117 e e e 25.6 3
Van der Bogt et al.2 42 94 44/50 41 111 51,35,25 e 901/281e 21/5e 0
Note. PFH ¼ positive family history; PBL ¼ peroperative blood loss; CND ¼ persistent cranial nerve damage.
a Only the abstract was available.
b Median instead of the mean.
c Shamblin I/II/III respectively.
d The ﬁrst value stands for the mean of the Shamblin group I and II, the second value is the mean for the Shamblin III group.
e The ﬁrst value refers to surgery following the standard procedure, while the second value represents results of the cranial-caudal
approach.
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with this study, with a mean blood loss of 145 mL in
Shamblin I and II tumors, and a mean of 263 mL in Shamblin
III tumors. However, despite this low blood loss, a consid-
erably higher rate of postoperative complications, reported
as persistent cranial nerve damage, was encountered in
14% of their patients.
Second, in the present study, patients suffering from
postoperative temporary neuropraxia all recovered spon-
taneously. This absence of persistent cranial nerve damage
after any of the CBT operations is remarkable, as other
studies report signiﬁcant occurrence of this disabling
complication. Lim et al.6 have reviewed 15 tumors and
experienced 23% persistent cranial nerve damage, although
it must be stated that this study included a relatively large
amount of complex Shamblin III tumors (n ¼ 8, 61%).
Kruger et al.10 described an incidence of 18.3% in a study of
49 CBTs in 39 patients, without providing exact information
regarding Shamblin classiﬁcation. Smaller studies per-
formed by Ma et al.11 and Ozay et al.8 showed comparable
rates of persistent cranial nerve damage to the present
study, although our study included considerably more
Shamblin III CBTs.
In the present study a trend has been noticed in the
chance of developing postoperative neuropraxia with
increasing peroperative blood loss. This emphasizes the
importance of a dry surgical ﬁeld, which facilitates the
identiﬁcation of the adjacent nerves, arteries, and veins.
The blood supply of the CBT is extensive and its main source
is the ascending pharyngeal artery.3 Although proximal
ligation of the external carotid artery could also lead to a
decrease in tumor blood ﬂow, preparation of the common
carotid artery and the proximal part of the external carotid
artery is a challenge in itself in case of a CBT. In this respect,a craniocaudal approach might be preferred because the
main blood supply of the CBT (the ascending pharyngeal
artery) is encountered at the tumor’s cranial side and
ligated at an early stage. This provides a dry surgical ﬁeld
and a decrease in tumor volume, and therefore facilitates
the dissection from adjacent structures.
Another way to prevent blood loss is pre-operative
embolization. However, precaution should be taken when
initiating embolization as side effects (e.g. distal migration
of the embolization medium) can be detrimental.17,18 At
some institutions pre-operative embolization is preferred
before surgical resection because this will lower the vol-
ume and blood ﬂow of the tumor. Consequently, the CBT
could be resected more easily with minimal blood loss.
Shah et al.19 recently published a study that investigated a
new medium for embolization, EVOH (ethylene vinyl
alcohol copolymer). No strokes and a mean of 55 mL blood
loss were reported. Kalani et al.20 showed that pre-
operative embolization, using a transfemoral transarterial
onyx technique, is a successful way to embolize the CBT.
Tumor devascularisation of 88% was achieved, with an
average peroperative blood loss of 192 mL. Although these
results are encouraging, other recently published studies
have shown less favorable outcomes. Gemmete et al.21
showed that there is a higher risk of developing stroke
secondary to pre-operative embolization in selected pa-
tients. With only one minor non-disabling stroke and
considering the minimal blood loss since the introduction
of the craniocaudal approach in 1992, pre-operative
embolization is not part of CBT management at our insti-
tution. Thus, in respect of peroperative blood loss, post-
operative complications, and overall safety, the current
ﬁndings show that craniocaudal CBT dissection provides a
dry surgical workﬁeld and compares favorably with the
628 M.P.M. Paridaans et al.conventional approach (starting at the bifurcation), either
with or without embolization.
In the current series, there is a high prevalence of he-
reditary CBT patients (56%, of which 74% suffered bilateral
CBT). The cause of this high percentage is to be attributed
to the high prevalence of patients with a SDHD mutation in
parts of the Netherlands. At our institution, because of the
high incidence of the mutation, family members of our
patients all receive screening. For this reason, we diagnose
relatively more CBTs at an early stage, allowing a generally
longer follow up before operation. The SDHD mutation is
known for its correlation to the development of para-
gangliomas, including CBT.16,22 Remarkably, among heredi-
tary cases with unilateral tumors (26%), all were right-sided
CBTs. Moreover, a greater part of all bilateral cases started
on the right side, and this was signiﬁcant (p ¼ .033). Further
research is currently ongoing and will explore the relation-
ship between CBT side and SDHD mutation, as well as its
clinical relevance.
Our previous study2 shows a relatively high percentage of
recurrence (17% of which 71% were hereditary cases) when
compared with recently published studies. This may be a
result of high incidence of hereditary cases in combination
with a screening-intensive longer period of follow up.
However, it can not be ruled out that this is due to irradical
resection, although it must be stated that, to date, no
recurrence from the current study group has been
diagnosed.
To date, there has not been a standard treatment for CBT.
The rareness of this tumor does not facilitate a large ran-
domized controlled trial for the best surgical approach or
non-surgical treatment to be assessed. For this reason, re-
sults achieved with the craniocaudal technique can only be
compared with the previously obtained results from our
institution or to other contemporary studies, which is
scientiﬁcally suboptimal. Specialists will persist to perform a
treatment that they are familiar with if this provides the
best result for their ability. This includes pre-operative
embolization that, as mentioned before, can lead to
acceptable results in experienced hands, but is not neces-
sary when similar results are achieved in a single surgical
session. This study shows once more that safe surgical
removal of CBT can be performed using the craniocaudal
technique. This adapted surgical technique combined with
further centralization of CBT surgery in national tertiary
referral centres will likely lead to a minimum of post-
operative morbidity. Based on the ﬁndings from our current
and former studies, which, taken together, are the largest
single-institution experience to date, we therefore suggest
that the craniocaudal approach should be the surgical
technique of choice for CBT resection.
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